Table 5.
Change in plasma arginine concentration from beginning to end of treatment periods
| Treatment | |||
|---|---|---|---|
| First value after start of treatment period | Last value available for treatment period | P-valuea | |
| During arginine treatment periods | |||
| Plasma arginine concentration, µmol/L | |||
| Mean (SD) | 56.0 (35.1) | 62.5 (49.8) | 0.76 |
| Median (Range) | 46.0 (3.0–166.0) | 49.0 (8.0–209.0) | |
| Data available (data missing), n | 37 (18) | 25 (30) | |
| During citrulline treatment periods | |||
| Plasma arginine concentration, µmol/L | |||
| Mean (SD) | 67.6 (56.6) | 84.9 (46.0) | 0.05 |
| Median (Range) | 55.0 (10.0–318.0) | 76.0 (39.0–231.0) | |
| Data available (data missing), n | 25 (7) | 19 (13) | |
| During arginine + citrulline treatment periods | |||
| Plasma arginine concentration, µmol/L | |||
| Mean (SD) | 62.0 (43.4) | 64.1 (38.6) | 0.60 |
| Median (Range) | 52.0 (7.0–265.0) | 58.0 (14.0–199.0) | |
| Data available (data missing), n | 54 (6) | 51 (9) | |
Data shown are per treatment period (total 147 periods) in the exposed population (N = 79)
aKruskal Wallis test
SD, standard deviation